Nasoaldo (Mometasone Furoate)

Mometasone furoate is a potent glucocorticoid that binds to intracellular glucocorticoid receptors in nasal mucosal cells. This binding modifies gene transcription, leading to decreased production of inflammatory cytokines, reduced vascular permeability, and suppression of immune cell activity, which together diminish nasal inflammation.

The specific dosing regimen for Nasoaldo is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Patients should follow the prescriber’s instructions and the product’s label for the correct number of sprays and frequency.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Nasoaldo.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Nasoaldo. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nasoaldo’s active ingredient, mometasone furoate, is a high‑potency corticosteroid with a favorable safety profile when used as directed. Compared with older nasal steroids such as beclomethasone, mometasone often requires fewer daily sprays to achieve similar symptom control, offering convenient dosing and reduced systemic exposure.

Store Nasoaldo at temperatures below 25 °C (77 °F). Keep the spray in its original packaging, protect it from moisture and direct heat, and ensure the cap is tightly closed when not in use to maintain product stability.

Nasoaldo is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and spray the prescribed number of sprays while breathing in gently. The process is then repeated in the other nostril if directed by the prescriber.

Serious risks, though rare, include fungal infection of the nasal mucosa, severe or persistent nosebleeds, adrenal suppression with prolonged high‑dose use, and systemic allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience any of these events.

Nasoaldo should not be used by individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It is also contraindicated in patients with active, untreated nasal infections or recent nasal surgery unless advised otherwise by a healthcare professional.